Mutations in the BRCA 1 or 2 genes significantly increase an individual’s risk of developing breast cancer, as well as several other cancer types. Breast cancers related to a BRCA mutation are also more likely to be triple-negative breast cancer (TNBC), which can be more aggressive and difficult to treat.
Previous studies have shown that targeted drug therapies may be more effective in treating BRCA-associated breast cancers than...
Results from a clinical trial led by MD Anderson researchers showed that combining the immunotherapy checkpoint inhibitor drug durvalumab...
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon form of ALCL that was first reported in 1996. The U.S....
For their role in transforming cancer care, three MD Anderson faculty received the American Society of Clinical Oncology’s Special Awards – the society’s highest honors – during its annual meeting in early June.
John Mendelsohn, M.D., received the Distinguished Achievement Award, which recognizes leadership or mentorship by a scientist, practitioner, or researcher in any oncology subspecialty that has benefited...
In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from MD Anderson Cancer...
In recognition of their contributions to basic, translational, and clinical research, six faculty members from MD Anderson Cancer Center have...
Practicing Tibetan yoga twice a week may reduce sleep disturbances and improve sleep quality for breast cancer patients receiving chemotherapy...
Early-stage breast cancer patients receiving a shorter course of whole-breast radiation with higher radiation doses reported equivalent cosmetic...
Distinguished contributions to understanding p53 tumor suppression in stem cells and breakthrough advances in treating breast cancer have...